Amgen Receives Positive CHMP Opinion To Expand Use Of Nplate ® (romiplostim) In Pediatric Patients With Chronic Immune Thrombocytopenic Purpura

Positive Opinion Based on Five Studies Demonstrating Nplate Reduces Rates of Bleeding in Children With Rare Blood Disorder THOUSAND OAKS, Calif., Nov. 10, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for Nplate® (romiplostim) to include the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) for patients one year of age and older who are refractory to other treatments (e.g., corticosteroids, immunoglobulins). The positive CHMP opinion was based on five studies evaluating the safety and ef...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news